Cancer supportive care

Cheng, C.J., Y.H. Chen, T. Chau, and S.H. Lin. 2004. A hidden cause of hypokalemic paralysis in a patient with prostate cancer. Support Care Cancer 12(11) 810-812. 

Hydroxylation or oxidative cleavage of the allylic methyl group present on the carbocyclic nonaromatic ring increases affinity for both CB receptors, as exemplified by the structure of nabilone (27), which has been introduced into the market as antiemetic agent for cancer supporting care and has also recently been approved in USA for the treatment of neuropathic pain [53]. The position of the double bond seems to be not crucial, indeed A -THC is almost equipotent with A -THC however, aromatization of this ring, as occurs in CBN, causes a marked decrease in affinity. 

The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (2006) Prevention of chemotherapy- and radiotherapy-induced emesis results of the Perugia International Antiemetic Consensus Conference. Ann Oncol 17 20-28... 

Cancer treatments have exploded technologically in the last couple of decades. The fields of radiation therapy, surgery, and pharmaceuticals have had numerous developments, so patients are receiving not only less toxic treatments but also treatments that have improved outcomes over those of 15 years ago. Supportive-care therapies have improved, so patients may be at... 

TABLE 96-3. Multinational Association for Supportive Care in Cancer (MASCQ Risk Index for Identifying Low-Risk Patients with Febrile Neutropenia7... 

It is clear that patients with febrile neutropenia represent a heterogeneous group. Some patients are at lower risk and potentially could be treated as outpatients, thereby avoiding the risk and cost of hospitalization. The Multinational Association for Supportive Care in Cancer (MASCC) has validated a risk-assessment tool that assigns a risk score to patients presenting with febrile neutropenia7 (Table 96-3). Patients with a risk-index score of 21 or greater are identified as low risk and are candidates for outpatient therapy (discussed under Treatment ). 

The major initial treatment modality for advanced prostate cancer is androgen ablation (e.g., orchiectomy or luteinizing hormone-releasing hormone [LHRH] agonists with or without antiandrogens). After disease progression, secondary hormonal manipulations, cytotoxic chemotherapy, and supportive care are used. 

Devine, S.M. and Wingard, J.R., Viral infections in severely immunocompromised cancer patients, Support Care Cancer, 2, 355, 1994. 

PDQ Physician Data Query. PDQ is an online database developed and maintained by the National Cancer Institute. Designed to make the most current, credible, and accurate cancer information available to health professionals and the public, PDQ contains peer-reviewed summaries on cancer treatment, screening, prevention, genetics, and supportive care a registry of cancer clinical trials from around the world and directories of physicians, professionals who provide genetics services, and organizations that provide cancer care. Most of this information is available on the CancerNet Web site, and more specific information about PDQ can be found at http //cancemet.nd.nih.gov/pdq.html. [NIH]... 

Supportive care Treatment given to prevent, control, or relieve complications and side effects and to improve the comfort and quality of life of people who have cancer, [nih]... 

Cunningham, D. et al.. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. The Lancet, 352, 1413-1418, 1998. 

Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000 18(10) 2095-2103. 

Homsi J, Walsh D, Nelson KA Psychostimulants in supportive care. Support Care Cancer 8 385-397, 2000... 

Davis MP, Walsh D Methadone for relief of cancer pain A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001 9 73. [PMID 11305074]... 

Mancini, I. and Bruera, E. Constipation in advanced cancer patients, Support. Care Cancer 1998, 6, 356-364. 

Sarhill, N., Walsh, D., Nelson, K.A. Hydromorphone pharmacology and clinical applications in cancer patients, Support. Care Cancer 2001, 9, 84-96. 

Davis, M.P., J. Varga, D. Dickerson, D. Walsh, et al., Normal-release and controlled-release oxycodone pharmacokinetics, pharmacodynamics, and controversy, Support. Care Cancer, 11(2), 84-92, 2003. 

KlaschikE, NauckF, Ostgathe C. Constipation-modern laxative therapy. Support Care Cancer. 2003 11 679-685. 

Tamayo AC, Diaz-Zuluaga PA. Management of opioid-induced bowel dysfunction in cancer patients. Support Care Cancer. 2004 12 613-618. 

Surgery can cure lung cancer, but only one in five patients are suitable for this treatment. If the tumor has not spread outside the chest and does not involve vital structures such as the liver, then surgical removal may be possible, but only if the patient does not also have severe bronchitis, heart disease, or other illnesses. Small cell lung cancer is treated with chemotherapy. Non-small cell cancer may be treated with radiotherapy and chemotherapy (as part of a research trial) or with supportive care. Radiotherapy is either radical or palliative. ... 

Tanaka K, Akechi T, Yamazaki M, Hayashi R, Nishiwaki Y, Uchitomi Y. Neuroleptic malignant syndrome during haloperidol treatment in a cancer patient. A case report. Support Care Cancer 1998 6(6) 536-8. 

Cesaro S, Calore E, Messina C, Zanesco L. Allergic reaction to the liposomal component of liposomal amphotericin B. Support Care Cancer 1999 7(4) 284-6. 

Lagman R, Walsh D. Dangerous nutrition Calcium, vitamin D, and shark cartilage nutritional supplements and cancer-related hypercalcemia. Support Care Cancer 2003 ll(4) 232-5. 

---